Candel Therapeutics Inc. has released a corporate presentation highlighting recent progress and key achievements in its clinical programs. The report details positive results for CAN-2409 (aglitimagene besadenovec), an off-the-shelf pan-solid tumor therapy, including favorable data from a phase 3 randomized placebo-controlled trial in localized, intermediate- to high-risk prostate cancer. Additional positive overall survival data were observed in randomized phase 2a clinical trials of CAN-2409 in both borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. The company also outlined a strong financial position, with cash and cash equivalents of $87.0 million as of September 30, 2025, and a term loan facility of up to $130 million established in October 2025. Precommercialization activities for CAN-2409 are underway to support a potential commercial launch following approval. Key anticipated milestones for 2025-2026 include updated clinical results in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma, as well as initiation of new phase 3 trials. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.
Comments